Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 9 - Drugs for disorders of the cardiovascular system
Patents for A61P 9 - Drugs for disorders of the cardiovascular system (159,484)
03/2005
03/30/2005EP1224163B1 Use of carbonylamino derivatives against cns disorders
03/30/2005EP1194429B1 Potassium channel openers
03/30/2005EP1194140B1 Pharmaceutical composition containing fenofibrate and preparation method
03/30/2005EP1124570A4 Novel neuropilin/growth factor binding and uses thereof
03/30/2005EP1091942B1 Potassium channel blocking agents
03/30/2005EP1075467B1 Pyrazole derivatives as p-38 map kinase inhibitors
03/30/2005EP1001978B1 Angiotensin derivatives
03/30/2005EP0980369B1 Sulfonamides for treatment of endothelin-mediated disorders
03/30/2005EP0877740B1 Thiol derivatives with metallopeptidase inhibitory activity
03/30/2005CN1602427A Inhibition of tristetraproline for protection of the heart from cardiac injuries
03/30/2005CN1602360A Methods of increasing endogenous erythropoietin (EPO)
03/30/2005CN1602317A Angiopoietin-2 specific binding agents
03/30/2005CN1602315A Polynucleotide constructs, pharmaceutical compositions and methods for targeted downregulation of angiogenesis and anticancer therapy
03/30/2005CN1602311A Use of 2-amino-4-pyridylmethyl-thiazoline derivatives as inhibitors of inducible NO-synthase
03/30/2005CN1602310A Benzothiazoles compound
03/30/2005CN1602307A Substituted 6h-dibenzo[c, h]chromenes as estrogenic agents
03/30/2005CN1602294A Acetyl l-carnitine salt with a dicarboxilic organic acid and process for preparing same
03/30/2005CN1602292A Unsaturated 1-amino-alkylcyclohexane NMDA, 5HT3 and neuronal nicotinic receptor antagonists
03/30/2005CN1602207A Methods for inhibiting ocular processes
03/30/2005CN1602197A Use of specific dose of fondaparinux sodium for the treatment of ACS
03/30/2005CN1602196A Ureas of 2-aminobenzothiazoles as adenosine modulators
03/30/2005CN1602191A Compounds and uses thereof for decreasing activity of hormone-sensitive lipase
03/30/2005CN1602187A Valdecoxib-based composition prepared by spray drying process and exhibiting rapid oral dissolution
03/30/2005CN1600817A Yellow pigment of safflower preparation method and application
03/30/2005CN1600755A General flavones of hawthorn fruit, preparation method and application
03/30/2005CN1600358A Combination of medication for curing hyperlipemia, arteriosclerosis, coronary heart disease and fatty liver
03/30/2005CN1600357A Effective position of pilose asiabell root, preparation, medication use and preparation method
03/30/2005CN1600335A Oral taking drug for treating bleeding from internal hemorrhoid and preparation method
03/30/2005CN1600322A Combination of propolis, preparation method and usage
03/30/2005CN1600319A Combination of Chinese traditional medicine for curing cardiovascular and cerebrovascular diseases
03/30/2005CN1600318A Combination of Chinese traditional medicine for curing cardiovascular diseases and cerebrovascular disease
03/30/2005CN1600314A Injection for venocylsis of diluted Diltiazem containing calcium channel blocker
03/30/2005CN1600305A Oral liquid prepared-from extractive of ginkgo leaf for anti heart and cerebral ischemia, and reducing blood fat and for enhancing memory
03/30/2005CN1600296A Method for preparing tiny pellets of difficult soluble drugs and formulation containing the pellets
03/30/2005CN1194978C Phosphinous and phosphonic acid derivs. used as medicaments
03/30/2005CN1194762C Gene therapy for cerebrovasclar disorders
03/30/2005CN1194757C Medical health oral liquid and its prepn
03/30/2005CN1194748C Medicine for treating hypertension and preparation method
03/30/2005CN1194741C Erigreron Breviscapus compound preparation
03/30/2005CN1194740C Chinese medicine powder treating cerebrovascular diseases
03/30/2005CN1194732C Medicine for treating coronary heart disease and angina pectoris and its prepn
03/30/2005CN1194730C Cardiac and cerebral blood vessel nourishing tea
03/30/2005CN1194729C Externally used medicine for curing piles
03/30/2005CN1194725C Apoplexia hemiplegic recovered capsule and preparing method thereof
03/30/2005CN1194724C Chinese medical preparation for treating coronary disease and angina pectoris and preparation thereof
03/30/2005CN1194716C Chinese patent drug made by using pseudo-ginseng and epimedium as raw material for curing coronary heart disease
03/30/2005CN1194709C Kidney invigorating and bone strengthening medicine and its preparing method
03/30/2005CN1194701C Application of icaritin or demethylicaritin in preparing estrogen receptor moderator
03/30/2005CN1194699C Compound Huanweihuangyangxing D tablet preparation
03/30/2005CN1194698C Puerarin injection and its prepn, process
03/29/2005US6872851 Melatonergic receptors; antiinflammatory agents; anticancer agents
03/29/2005US6872746 Isomeric fused pyrrolocarbazoles and isoindolones
03/29/2005US6872738 Product comprising at least a no synthase inhibiting substance associated with at least a phospholipase a2 inhibiting substance
03/29/2005US6872737 Drugs such as 4-Benzyl-2-methyl-1,2,4-thiadiazolidine-3,5 -dione inhibitors of glycogen synthase kinase-3 (GSK-3), for prophylaxis of neurodegenerative disorders, cancer, hyperplasia, psoriasis, arteriosclerosis or restinosis
03/29/2005US6872733 Benzimidazolone compounds
03/29/2005US6872732 Heterocyclic derivatives and medicinal use thereof
03/29/2005US6872730 Substituted benzofurans and benzothiophenes, methods of making and methods of use as integrin antagonists
03/29/2005US6872722 Therapies for tissue damage resulting from ischemia
03/29/2005US6872721 Derivatives of 2,3,6,7,12,12a-hexahydropyrazino-[1′,2′:1,6]pyrido[3,4b]-indole-1,4-dione
03/29/2005US6872719 Antiinflammatory agents; autoimmune disease
03/29/2005US6872718 Tricyclic dihydrobenzofuran derivatives, process for the preparation thereof and agents
03/29/2005US6872711 β-substituted β-aminoethyl phosphonate derivatives
03/29/2005US6872702 Cyclic peptide; antitumor agents; antiinflammatory agents; tissue remodeling
03/29/2005US6872409 For inhibiting platelet aggregation, for prolonging bleeding time
03/29/2005CA2392879C A pyrrolidineacetamide derivative alone or in combination for treatment of cns disorders
03/29/2005CA2301732C Therapeutic combinations
03/29/2005CA2280447C Pyrrolo¬1,2-a|pyrazine derivatives as 5ht1a ligands
03/29/2005CA2268870C Heterocyclic carboxamides
03/29/2005CA2261760C Sulfonamides and derivatives thereof that modulate the activity of endothelin
03/29/2005CA2217169C Thienyl-, furyl-, pyrrolyl- and biphenylsulfonamides and derivatives thereof that modulate the activity of endothelin
03/29/2005CA2182582C Compositions containing micronized nebivolol
03/29/2005CA2180950C Kallikrein-inhibiting "kunitz domain" proteins and analogues thereof
03/29/2005CA2176042C Alpha-aryl or heteroaryl-substituted amide ester acat inhibitors
03/29/2005CA2097444C Angiotensin ii antagonist imidazole derivatives, their preparation and their therapeutic use
03/24/2005WO2005026741A2 Non-peptide agonists and antagonists of adrenomedullin and gastrin releasing peptide
03/24/2005WO2005026728A1 Screening method
03/24/2005WO2005026348A1 Screening method
03/24/2005WO2005026343A1 Method of promoting subsistence and/or proliferation of neural stem cell and promoting extension of neurite, promoter therefor, pharmaceutical composition containing neural stem cell, method of assay and method of screening
03/24/2005WO2005026198A1 Base-substituted benzylamine analogs for use as coagulation factor xa inhibitors, the production and use thereof
03/24/2005WO2005026160A1 Crystal of heterocyclic compound
03/24/2005WO2005026117A1 Preventive for cerebral stroke recurrence
03/24/2005WO2005025674A1 Combination of phenylcarboxamides with beta-adrenergic receptor blockers and use thereof for the treatment of atrial arrhythmias
03/24/2005WO2005025600A1 Drug inhibiting mobilization of adhesive cells into peripheral blood
03/24/2005WO2005025584A1 Use of adipose tissue cells for initiating the formation of a functional vascular network
03/24/2005WO2005025566A1 Oral pharmaceutical formulations containing the active ingredient irbesartan
03/24/2005WO2005025520A2 Chitosan spinning method, device therefor, and resulting chitosan yarn, and uses thereof
03/24/2005WO2005012355B1 Bioactive peptides derived from the proteins of egg white by means of enzymatic hydrolysis
03/24/2005WO2005009419A3 Use of 5-methoxytryptamine as a cardioprotective agents
03/24/2005WO2005004789A3 Method for treating diseases associated with changes of qualitative and/ quantitative composition of blood extracellular dna
03/24/2005WO2004110379A3 A1 adenosine receptor antagonists
03/24/2005WO2004096116A3 Diazabicyclononene derivatives
03/24/2005WO2004092379A3 Method for treatment of angiogenic disorders
03/24/2005WO2004092378A3 Method for treatment of cancerous angiogenic disorders
03/24/2005WO2004025270A3 Methods for measuring rates of reserve cholesterol transport in vivo, as an index of anti-atherogenesis
03/24/2005WO2004000204A3 Labelled somatostatin analogs backbone cyclized through metal complexation
03/24/2005WO2003103478A3 Methods for using adamts-12, an integrin and metalloprotease with thrombospondin motifs
03/24/2005WO2003094856A3 1l1rl-1 as a cardiovascular disease marker and therapeutic target
03/24/2005WO2002092759A9 Molecules for disease detection and treatment
03/24/2005US20050065210 Anticholesterol agents; antilipemic agents; arteriosclerosis; cardiovascular disorders; parasiticides; antitumor agents; antiproliferative agents; antidiabetic agents
03/24/2005US20050065209 Citalopram for the treatment of elevated blood pressure
1 ... 799 800 801 802 803 804 805 806 807 808 809 810 811 812 813 814 815 816 817 818 819 ... 1595